insights_auto
Why is KYNB up 2,52%?
Dive Deeperchevron_right
KYNB:NASDAQ
Kyntra Bio Inc
6,11 $
arrow_upward
+2,52%(+0,15) 1D
9 հոկ, 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for KYNB...
Open
6,08 $
High
6,26 $
Low
6,08 $
Mkt. cap
24,74 մլն
Avg. vol.
25,82 հզր
Volume
6,56 հզր
P/E ratio
0,13
52-wk high
9,70 $
52-wk low
5,62 $
EPS
45,30 $
Beta
1,05
Shares outstanding
4,05 մլն
No. of employees
34
Open
6,08 $
High
6,26 $
Low
6,08 $
Mkt. cap
24,74 մլն
Avg. vol.
25,82 հզր
Volume
6,56 հզր
P/E ratio
0,13
52-wk high
9,70 $
52-wk low
5,62 $
EPS
45,30 $
Beta
1,05
Shares outstanding
4,05 մլն
No. of employees
34
News stories
From web sources and news partners
Yahoo Finance
·
10 ժամ առաջ
A COVID Vaccine Stock on the S&P 500 Is Up 600% This Year
24/7 Wall St.
·
1 օր առաջ
Why "VOO and Chill" Lost Money for 8 Straight Years: What $100,000 in the S&P 500 Did From 2000 to 2008
MarketWatch
·
22 ժամ առաջ
S&P 500 at 10,000 or bust: New ETF offers investors all-or-nothing bet on the index
Seeking Alpha
·
18 ժամ առաջ
The 1-Minute Market Report October 10, 2026 (NYSEARCA:VOO)
Profile
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
About Kyntra Bio Inc
CEO-
Employees34
Founded01 հնվ, 1993 թ.
HeadquartersՍան Ֆրանցիսկո, Կալիֆոռնիա, Միացյալ Նահանգներ
Sector-
Websitekyntrabio.com